Rakovina Therapeutics Inc. (RKV.V)
| Previous Close | 0.0700 |
| Open | 0.0650 |
| Bid | 0.0600 x N/A |
| Ask | 0.0650 x N/A |
| Day's Range | 0.0650 - 0.0650 |
| 52 Week Range | 0.0650 - 0.1800 |
| Volume | |
| Avg. Volume | 8,420 |
| Market Cap | 4.539M |
| Beta (5Y Monthly) | -0.04 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients through development of novel DNA-damage response inhibitor therapeutics, announced financial results for the quarter ended September 30, 2023, and provided a corporate update. Corporate highlights during the past quarter included: On November 27, 2023, we announced the appointment of Prof. Artem Cher
- GlobeNewswire
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response inhibitors (DDRi) to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Artem Cherkasov to the Company’s Scientific Advisory Board. Prof. Cherkasov is a Professor in the Department of Urologic Sciences, Faculty of Medicine at the University of B
- GlobeNewswire
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage response (DDR) inhibitors to address high unmet medical needs in the treatment of cancer, today announced the appointment of Prof. Petra Hamerlik, Chair of Translational Neuro-Oncology at the University of Manchester and former CNS Cancer Bioscience Lead at AstraZeneca plc, to its Scientific Advisory Boa
